Loading publications…
The last 5 uploaded publications
Data from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric‐Bernstam, Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V. Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason J. Luke, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa Kattenhorn, Marc R. Pelletier, Shahneen Sandhu (2023). Data from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. , DOI: https://doi.org/10.1158/1078-0432.c.6532847.
Preprint61 days agoData from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V. Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason J. Luke, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa Kattenhorn, Marc R. Pelletier, Shahneen Sandhu, Funda Meric‐Bernstam (2023). Data from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. , DOI: https://doi.org/10.1158/1078-0432.c.6532847.v1.
Preprint61 days agoSupplementary Data1 from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric‐Bernstam, Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V. Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason J. Luke, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa Kattenhorn, Marc R. Pelletier, Shahneen Sandhu (2023). Supplementary Data1 from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. , DOI: https://doi.org/10.1158/1078-0432.22488965.v1.
Preprint61 days agoSupplementary Data1 from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric‐Bernstam, Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V. Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason J. Luke, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa Kattenhorn, Marc R. Pelletier, Shahneen Sandhu (2023). Supplementary Data1 from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. , DOI: https://doi.org/10.1158/1078-0432.22488965.
Preprint61 days agoCombination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric‐Bernstam, Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V. Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason J. Luke, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa Kattenhorn, Marc R. Pelletier, Shahneen Sandhu (2022). Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. , 29(1), DOI: https://doi.org/10.1158/1078-0432.ccr-22-2235.
Article61 days ago